Crossmark

Epidemiology and health care utilization of patients suffering from Huntington’s disease in Germany: real world evidence based on German claims data

Published Online: 2019-12-10

Published Print: 2019-12

Authors

Ohlmeier, Christoph

Saum, Kai-Uwe

Galetzka, Wolfgang

Beier, Dominik

Gothe, Holger
Funding

Funding for this research was provided by:

Roche Pharma AG (Not applicable)
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-10
More Information

Article History

Received: 12 July 2019

Accepted: 5 December 2019

First Online: 10 December 2019

Ethics approval and consent to participate

: All patient-level data in the InGef research database are de-identified to comply with German data protection regulations. Use of the study database for health services research is therefore fully compliant with German federal law and, accordingly, institutional review board/ethical approval and informed consent of the patient was not needed.

: Not applicable.

: This study was funded by Roche Pharma AG. The authors had complete autonomy for the process of establishing the protocol, carrying out the analyses and interpreting the results. This also includes the full right to publish the results without limitation.

Document is current